GlassScriptPhysician profile
Joseph Friddle
NPI 1487988838
$10,372.92
in general payments reported to CMS, 2019-2025
31 companies · $2,076 in 2025
The $2,076 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,426 · 2022: $1,556 · 2023: $2,531 · 2024: $2,784 · 2025: $2,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,379 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,378.86 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,453.05 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,163.63 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,154.55 | 2021-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $714.12 | 2021-2025 | Trintellix |
| Lundbeck LLC | $703.32 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $546.05 | 2023-2025 | Auvelity |
| Tris Pharma INC | $505.32 | 2022-2025 | Dyanavel Xr |
| Corium, LLC | $499.61 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $497.59 | 2021-2024 | Qelbree, Qelbree |
| Alkermes, INC. | $390.15 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $360.23 | 2021-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $346.34 | 2021-2022 | |
| Bausch Health US, LLC | $326.24 | 2021-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $293.51 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Janssen Pharmaceuticals, INC | $233.61 | 2021-2025 | Spravato |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $183.36 | 2021-2024 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $137.97 | 2021-2024 | Jornay Pm |
| Eisai INC. | $129.27 | 2021-2022 | |
| Almatica Pharma LLC | $123.79 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Noven Therapeutics, LLC | $119.34 | 2024-2025 | Xelstrym, Secuado |
| Merck Sharp & Dohme LLC | $101.15 | 2021-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $86.85 | 2022-2025 | Quviviq, Quviviq |
| Neurocrine Biosciences, INC. | $73.39 | 2024-2025 | Ingrezza |
| Harmony Biosciences LLC | $42.52 | 2023-2025 | Wakix |
| Tonix Medicines, INC. | $39.51 | 2025 | Tonmya |
| Avanir Pharmaceuticals, INC. | $35.25 | 2021 | |
| Collegium Pharmaceutical, INC. | $33.99 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.99 | 2024 | |
| Adlon Therapeutics L.P. | $21.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.02 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Friddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.